Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate

Patent metadata

Field	Value
Publication number	US-9650435-B2
Application number	US-201414263517-A
Country	US
Kind code	B2
Filing date	Apr 28, 2014
Priority date	Nov 14, 2008
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

Isolated monoclonal antibodies that bind to HIV-2 isolate NWK08F are provided. In some embodiments, the antibodies bind a polypeptide comprising the HIV-2NWK08F Env, Pol, or Nef proteins, or fragments thereof, respectively. Antigen-binding fragments and humanized versions of the antibody are also provided.

First claim

What is claimed is:

1. An isolated monoclonal antibody, or fragment thereof, that specifically binds to a human immunodeficiency virus type 2 (HIV-2) deposited as HIV-2NWK08F, wherein the antibody does not specifically bind to a polypeptide with the amino acid sequence of SEQ ID NO: 5.

2. The antibody of claim 1 , wherein the antibody or fragment thereof binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:6, or a fragment thereof.

3. The antibody of claim 1 , wherein the antibody is humanized.

4. The antibody of claim 1 , wherein the fragment is selected from the group consisting of Fab, F(abγ) 2 , Fv, single chain antibodies (scFv), and domain antibodies (dAbs).

5. A composition for detecting HIV-2NWK08F polypeptides comprising the antibody of claim 1 .

6. A monoclonal antibody specific for an HIV-2NWK08F polypeptide produced by a method comprising:
a. immunizing a mammal with an HIV-2NWK08F polypeptide having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:6, or an immunogenic fragment thereof;
b. isolating immunized splenocytes from said mammal;
c. fusing the immunized splenocytes with a myeloma cell line to produce hybridomas;
d. selecting for the hybridomas by culturing in selective media;
e. clonally expanding the hybridomas in appropriate culture media; and,
f. identifying and characterizing those hybridomas that produce monoclonal antibodies specific for an HIV-2NWK08F polypeptide.

7. The antibody of claim 2 , wherein the antibody is humanized.

8. The antibody of claim 2 , wherein the fragment is selected from the group consisting of Fab, F(abγ) 2 , Fv, single chain antibodies (scFv), and domain antibodies (dAbs).

9. A composition for detecting HIV-2NWK08F polypeptides comprising the antibody of claim 2 .

10. The antibody of claim 2 , wherein the antibody or fragment thereof binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:2, or a fragment thereof.

11. The antibody of claim 2 , wherein the antibody or fragment thereof binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment thereof.

12. The antibody of claim 2 , wherein the antibody or fragment thereof binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:6, or a fragment thereof.

Assignees

• Tulane Univ Health And Sciences Center
• The Administrators Of The Tulane Educational Fund

Inventors

• Smith Stephen M
• Marx Jr Preston A

Classifications

• C07K16/114 Primary

  Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV] · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• G01N2333/16

  HIV-1, HIV-2 · CPC title